Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

South Africa's Aspen expands further into Asia with Sandoz China deal

Published 04/12/2023, 07:36
Updated 04/12/2023, 19:45
© Reuters. FILE PHOTO: An Aspen Pharmacare logo is seen at outside company offices in Woodmead, Johannesburg, South Africa, September 13, 2018. REUTERS/Siphiwe Sibeko/File Photo

By Nqobile Dludla

JOHANNESBURG (Reuters) -Aspen Pharmacare is expanding further into China through a deal to buy the Chinese business of Swiss group Sandoz (SIX:SDZ) for up to 92.6 million euros ($100.6 million), the South African company said on Monday.

As part of the deal, Aspen Global Incorporated, a subsidiary of Aspen, will also buy the selling and intellectual property rights of a portfolio of established products that include Sandostatin, Aclasta and Voriconazole.

The rights will also cover a pipeline of products to be launched by Sandoz China in the short to medium term.

The deal "represents an attractive opportunity for Aspen to take a major step in its stated objective of increasing its presence in China," the company said.

Aspen said it will pay up to 92.6 million euros, with 18.5 million euros contingent upon the sales performance of the products in the pipeline. The pharma giant will fund the net upfront cash from existing debt facilities.

Additionally, Aspen will dispose of the commercialisation rights and related intellectual property for four anaesthetic products currently sold by Aspen in the European Economic Area to Sandoz.

For the disposal, it will receive up to 55.5 million euros, with 9.3 million euros contingent on the sales performance of its anaesthetic products, namely Nimbex, Tracrium, Carbocaine and Naropin.

"The disposal will allow Aspen's European management to adopt a more focussed approach to its remaining anaesthetic products in the region," Aspen said.

It added that those drugs it is selling "will be complementary to Sandoz's existing pharmaceutical offering in Europe, where it has significant scale and is well positioned to leverage their potential".

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Aspen is targeting to add about 1.8 billion rand ($96.23 million) of annual sales to the group from the Chinese business, while the sales of the anaesthetic products during Aspen's financial year ended June 30 were about 280 million rand.

The deals are expected to be completed in the second quarter of next year.

($1 = 0.9205 euros)

($1 = 18.7048 rand)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.